Clinical Handbook of Psychotropic Drugs 25th Edition by Ric M. Procyshyn

• 25th Edition
• Digital Download
• by Ric M. Procyshyn (Editor), Kalyna Z. Bezchlibnyk-Butler (Editor), David D. Kim (Editor)

Quick and comprehensive information on psychotropic drugs for adults.

– Accurate and up to date
– Comparison charts help decision-making
– Icons and full color
– Available in print and online
– Downloadable patient info sheets
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

• Independent, unbiased, up to date
• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:

• Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
• Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
• Mood Stabilizers sections on Lithium and Anticonvulsants extensively revised
• Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer’s disease
• Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
• Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
• New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)